Allergan

4Q Revenues: $3.9 billion (+7%)

4Q Earnings: $1.2 billion (loss of $629.3 million 4Q15)

FY Revenues: $14.6 billion (+15%)

FY Earnings: $15.0 billion (earnings were $3.9 billion FY15)

Comments: Growth in the quarter was driven by BOTOX Cosmetic, with $199.4 million in sales, up 18% reflecting continued volume growth, and BOTOX Therapeutic revenues of $313.5 million, up 14%. KYBELLA, which launched in August, had sales of $12 million in the quarter. LINZESS sales were $173.6 million in the quarter, up 34% driven primarily by strong demand and continued OTC conversion. RESTASIS revenues were $393.1 million in the quarter, up 13% driven by demand and pricing. Earnings include discontinued operations.